Le-duy D. Do

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Clinical and tumor features of patients with immune checkpoint inhibitor-related neurological disorders and anti-Yo antibodies.

Clinical and tumor features of patients with immune checkpoint inhibitor-related neurological disorders and anti-Yo antibodies.

Journal: Therapeutic advances in neurological disorders

Published: May 05, 2025

Utility of tissue-based assays to elucidate an autoantibody-negative paraneoplastic syndrome: Lessons from a case report.

Utility of tissue-based assays to elucidate an autoantibody-negative paraneoplastic syndrome: Lessons from a case report.

Journal: Revue neurologique

Published: February 13, 2025

Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia.

Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia.

Journal: Cerebellum (London, England)

Published: July 31, 2024

Anti-RGS8 paraneoplastic cerebellar ataxia is preferentially associated with a particular subtype of Hodgkin's lymphoma.

Anti-RGS8 paraneoplastic cerebellar ataxia is preferentially associated with a particular subtype of Hodgkin's lymphoma.

Journal: Journal of neurology

Published: July 04, 2024

Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.

Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.

Journal: Journal of neurology

Published: November 29, 2023

Correction to: Autoimmune Cerebellar Ataxia Associated with Anti-Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity.

Correction to: Autoimmune Cerebellar Ataxia Associated with Anti-Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity.

Journal: Cerebellum (London, England)

Published: March 13, 2023

Autoimmune Cerebellar Ataxia Associated with Anti-Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity.

Autoimmune Cerebellar Ataxia Associated with Anti-Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity.

Journal: Cerebellum (London, England)

Published: January 19, 2023

The expanding spectrum of antibody-associated cerebellar ataxia: report of two new cases of anti-AP3B2 ataxia.

The expanding spectrum of antibody-associated cerebellar ataxia: report of two new cases of anti-AP3B2 ataxia.

Journal: Journal of neurology

Published: December 28, 2022

Anti-AGO1 Antibodies Identify a Subset of Autoimmune Sensory Neuronopathy.

Anti-AGO1 Antibodies Identify a Subset of Autoimmune Sensory Neuronopathy.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 28, 2022

Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies.

Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies.

Journal: Frontiers in immunology

Published: June 17, 2022

Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases.

Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: January 05, 2021

Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis.

Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: September 08, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026